Phase I Study of Vandetanib (ZD 6474) and Bevacizumab Combination Therapy Evaluating the VEGF and EGF Signal Transduction Pathways in Adults With Solid Tumors and Lymphomas.
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2012
At a glance
- Drugs Bevacizumab (Primary) ; Vandetanib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 15 Mar 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 15 Mar 2012 Actual end date changed from Jun 2010 to Feb 2011 as reported by ClinicalTrials.gov.
- 23 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.